Selected coverage of mantle cell lymphoma (MCL) from the 65th American Society of Hematology Annual Meeting and Exposition, December 9-12, 2023, San Diego, California. Patients with TP53-mutant mantle ...
Pirtobrutinib demonstrated efficacy in MCL and CLL/SLL, with over 70% of MCL and 80% of CLL/SLL patients reporting stable or improved symptoms. The BRUIN phase 1/2 study highlighted significant ...
Calquence, a BTK inhibitor, is now approved for first-line treatment of MCL, offering a new therapeutic option for patients ineligible for stem cell transplantation. The ECHO trial showed significant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results